Navigation Links
Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 6
Date:8/4/2009

SEATTLE, Aug. 5 /PRNewswire-FirstCall/ -- On Thursday, August 6, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the Company's 2009 second quarter financial results.

    Conference Call Numbers
    Thursday, August 6
    8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
    1-877-941-9205 (US Participants)
    1-480-629-9835 (International)

    Call-back numbers for post-listening available at 10:30 a.m. Eastern:
    1-800-406-7325 (US Participants)
    1-303-590-3030 (International)
    Passcode: 4130004#

    Live audio webcast at www.celltherapeutics.com will be archived for post
    listening approximately two hours after call ends.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: media@ctiseattle.com
    www.celltherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
11. Cell Therapeutics, Inc. Announces $6.5 Million Offering

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)...he holiday season is filled with get-togethers wit...s. It can also be stressful and tiring at times. E...gue, and high fat foods -- factors that can, over ... National Foundation for Cancer Research has devel...re a happier, more healthful holiday season, and c...
(Date:11/21/2009).... 21 DNC Chairman Tim K...te voted to begin full debate of health insurance ...com.com/cgi-bin/prnh/20080519/DNCLOGO ) ,, "T... road to enacting health insurance reform. By clea...ow have an opportunity to debate the health reform...
(Date:11/21/2009)...scusses Key Provisions of Legislation, Continues P...CHARLES, Ill., Nov. 21 ...he landmark Affordable Health Care for America Act...orm legislation forward, Congress has taken decisi...stem. Today, AARP hosted an educational forum to ...
(Date:11/21/2009)...APPYneuron,s most popular and addictive game, Spli...uch. , Mountain View, CA ...pular and addictive game, SplitWords, is now avail...designed to help banish that ,tip of the tongue, s... game challenges the brain by encouraging users t...
(Date:11/20/2009)...logist Closer to Understanding Brain Wiring and Di...swire/ -- Dr. Jeremy Schmahmann, Professor of Neur... the Massachusetts General Hospital in Boston, on ...research on the new field of study called "Connect..., Dr. Schmahmann is an award-winning leader in ...
Breaking Medicine News(10 mins):Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 2Health News:Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research 3Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2
...anada’s second anthrax outbreak has claimed the li...the Canadian Prairies.// Anthrax is caused by...imal that had become exposed in soil following flo... has reported that the latest outbreak has killed ...
...etting in motion the process to review the functio...he Centre's Expert Committee has sought details ab... The four-member committee, set up in the backdro...and reports of earlier committees which had review...
...IV positive female drug injection users in US and ...cted partners, according to a new study. // "...ple were having sex with at-risk male partners, an... Journal of Acquired Immune Deficiency Syndromes. ...
...ndian biotech major Biocon Ltd has roped in Bayer ... Insugen in the Chinese market, the company //said...ed biotech firm plans to launch Insugen in China b...her countries in the Asia-Pacific region later. Th...
...TI International Distinguished Fellow and Director... F. Ivy Carroll, Ph.D., has been presented //the C...n B. Eddy Memorial Award for outstanding research ...ments, Carroll developed RTI-336 and JDTic, two ph...
...ccording to the study conducted by the Queen's Uni...ing how genes work to protect the aortic muscle ne...ients suffering from arteriosclerosis. It is o...ase-1 (HO-1) markedly protects the arteriosclerois...
Other Medicine News:Health News:Bayer to Market Biocon Insulin in China 2Health News:Scientist Recognized for Drug Addiction Research 2Health News:Genes Identified To Protect Heart Muscles 2
(Date:11/20/2009)...e-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: B... September 30, 2009 with net earnings of $128,000,...,000. This compares to net earnings of $328,000, ...000 for the first quarter of last year. ,, Comm...ent and CEO Steve Springrose said: "Biotel enjoyed...
(Date:11/20/2009)... BD (Becton, Dickinson an...letion of its acquisition of HandyLab, Inc., an An...manufactures molecular diagnostic assays and autom...b announced an exclusive agreement for BD to devel...Lab Jaguar(TM) platform, the first fully integrate...
(Date:11/19/2009)...wswire/ -- Warner Chilcott plc (Nasdaq: WCRX ) to...ced secondary offering of 20,000,000 of its ordina...hare. The selling shareholders include funds affi...nking, J.P. Morgan Partners (advised by CCMP Capit...r institutional investors and members of the Compa...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Ikaria 28R 29 Names New Chairman 14523 1Ikaria 28R 29 Names New Chairman 14523 2Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7
... groups set out to confirm potential benefits of a...th breast cancer, PARIS, May 27 A new internatio...er is open for enrollment. The pivotal BETH,(BEvac...sitive Breast,Cancer) study is a Phase III clinica...s of combining two monoclonal antibodies, the anti...
...on A/S Today Announces That it has Entered Into a ...ity of Texas M. D., Anderson Cancer Center to De... Cancer, VEDBAEK, Denmark...alue gene expression analysis products, today,anno...agreement with the,Kleberg Center for Molecular Ma...
Other Medicine Technology:First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 2First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 3First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 4Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center 2Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center 3
...CellaVision DM96 is an Automated Digital Cell Morp...e-classification/characterization, display, storag...es. Up to 96 stained peripheral blood smears can b... 60 per hour depending on the tests requested. Usi...
Cystoscopy "T". Drape, Sterile
Urological Drape
... the Penilab IV and the Penilab V have an exceptio...tal studies. Model 1060 is similar to the Model 1... can one be added later. The Penilab V has a Dopp... of the accessories you'll need to get started. L...
Medicine Products: